These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 25110227)

  • 1. Dramatic lowering of very high Lp(a) in response to niacin.
    Li M; Saeedi R; Rabkin SW; Frohlich J
    J Clin Lipidol; 2014; 8(4):448-50. PubMed ID: 25110227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variance in niacin response in individuals with elevated lipoprotein(a).
    Safarova MS; Ezhov MV
    J Clin Lipidol; 2014; 8(6):646-647. PubMed ID: 25499949
    [No Abstract]   [Full Text] [Related]  

  • 3. Reply: To PMID 25110227.
    Saeedi R; Li M; Rankin S; Frohlich J
    J Clin Lipidol; 2014; 8(6):647. PubMed ID: 25499950
    [No Abstract]   [Full Text] [Related]  

  • 4. Niacin improves lipid profile but not endothelial function in patients with coronary artery disease on high dose statin therapy.
    Philpott AC; Hubacek J; Sun YC; Hillard D; Anderson TJ
    Atherosclerosis; 2013 Feb; 226(2):453-8. PubMed ID: 23174368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination treatment with atorvastatin plus niacin provides effective control of complex dyslipidemias: a literature review.
    McKenney JM
    Postgrad Med; 2012 Jan; 124(1):7-20. PubMed ID: 22314110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined use of extended-release niacin and atorvastatin: safety and effects on lipid modification.
    Sang ZC; Wang F; Zhou Q; Li YH; Li YG; Wang HP; Chen SY
    Chin Med J (Engl); 2009 Jul; 122(14):1615-20. PubMed ID: 19719960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
    Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K
    Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of extended-release niacin and atorvastatin monotherapies and combination treatment of the atherogenic lipid profile in diabetes mellitus.
    Van JT; Pan J; Wasty T; Chan E; Wu X; Charles MA
    Am J Cardiol; 2002 Jun; 89(11):1306-8. PubMed ID: 12031735
    [No Abstract]   [Full Text] [Related]  

  • 9. [Pleiotropic effects of nicotinic acid therapy in men with coronary heart disease and elevated lipoprotein(a) levels].
    Safarova MS; Trukhacheva EP; Ezhov MV; Afanas'eva OI; Afanas'eva MI; Tripoten' MI; Liakishev AA; Pokrovskiĭ SN
    Kardiologiia; 2011; 51(5):9-16. PubMed ID: 21649590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lowering of lipoprotein(a) level under niacin treatment is dependent on apolipoprotein(a) phenotype.
    Artemeva NV; Safarova MS; Ezhov MV; Afanasieva OI; Dmitrieva OA; Pokrovsky SN
    Atheroscler Suppl; 2015 May; 18():53-8. PubMed ID: 25936305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increase in circulating levels of adiponectin after treatment with statin and fibrate in patients with coronary artery disease and hyperlipidemia.
    Nakamura T; Kodama Y; Takano H; Umetani K; Fujioka D; Saito Y; Kawabata K; Obata JE; Kitta Y; Kobayashi T; Mende A; Kugiyama K
    Atherosclerosis; 2007 Aug; 193(2):449-51. PubMed ID: 16997309
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of CETP polymorphism on atorvastatin lipid-regulating effect and clinical prognosis of patients with coronary heart disease.
    Gu GL; Xu XL; Yang QY; Zeng RL
    Med Sci Monit; 2014 Dec; 20():2824-9. PubMed ID: 25547030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What can I do to lower my lipoprotein(a) level?
    Heart Advis; 2008 Apr; 11(4):8. PubMed ID: 18697235
    [No Abstract]   [Full Text] [Related]  

  • 14. Lipoprotein (a): perspectives from a lipid-referral program.
    Rubenfire M; Vodnala D; Krishnan SM; Bard RL; Jackson EA; Giacherio D; Brook RD
    J Clin Lipidol; 2012; 6(1):66-73. PubMed ID: 22264576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What does the future hold for niacin as a treatment for hyperlipidaemia and cardiovascular disease?
    Ahmed MH
    J Cardiovasc Med (Hagerstown); 2010 Nov; 11(11):858-60. PubMed ID: 20686417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trial clouds use of niacin with a statin.
    Harv Heart Lett; 2011 Aug; 21(12):2. PubMed ID: 21991606
    [No Abstract]   [Full Text] [Related]  

  • 18. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial.
    Fraley AE; Schwartz GG; Olsson AG; Kinlay S; Szarek M; Rifai N; Libby P; Ganz P; Witztum JL; Tsimikas S;
    J Am Coll Cardiol; 2009 Jun; 53(23):2186-96. PubMed ID: 19497447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of atherosclerosis with aggressive lipid lowering.
    Farmer JA
    Curr Atheroscler Rep; 2005 Mar; 7(2):86-7. PubMed ID: 15727721
    [No Abstract]   [Full Text] [Related]  

  • 20. Prognostic significance of elevated lipoprotein(a) in coronary artery revascularization patients.
    Kwon SW; Lee BK; Hong BK; Kim JY; Choi EY; Sung JM; Rhee JH; Park YM; Ma DW; Chung H; Mun HS; Lee SJ; Park JK; Min PK; Yoon YW; Rim SJ; Kwon HM
    Int J Cardiol; 2013 Sep; 167(5):1990-4. PubMed ID: 22633779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.